Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.

Duan YF, Li DF, Liu YH, Mei P, Qin YX, Li LF, Lin QX, Li ZJ.

Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):204-9.

PMID:
23558076
[PubMed - indexed for MEDLINE]
Free Article
2.

Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma.

Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang L, Ding Y.

J Gastroenterol Hepatol. 2012 Jun;27(6):1117-25. doi: 10.1111/j.1440-1746.2011.07049.x.

PMID:
22168621
[PubMed - indexed for MEDLINE]
3.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
[PubMed - indexed for MEDLINE]
4.

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.

Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B, Soucek P.

Cancer Chemother Pharmacol. 2013 Sep;72(3):669-82. doi: 10.1007/s00280-013-2246-2. Epub 2013 Aug 11.

PMID:
23934321
[PubMed - indexed for MEDLINE]
5.

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625.

PMID:
19824059
[PubMed - indexed for MEDLINE]
6.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

PMID:
22285706
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049
[PubMed - indexed for MEDLINE]
8.

EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.

Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, Haberler C, Aronica E, Vandertop WP, Noske DP, Würdinger T.

Clin Cancer Res. 2012 Aug 1;18(15):4048-58. Epub 2012 Jun 13.

PMID:
22696229
[PubMed - indexed for MEDLINE]
Free Article
9.

Overexpression of IQGAP1 in human pancreatic cancer.

Wang XX, Li XZ, Zhai LQ, Liu ZR, Chen XJ, Pei Y.

Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):540-5.

PMID:
24103286
[PubMed - indexed for MEDLINE]
Free Article
10.

EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.

Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M.

Oncogene. 2014 May 8;33(19):2454-63. doi: 10.1038/onc.2013.204. Epub 2013 Jun 10.

PMID:
23752186
[PubMed - indexed for MEDLINE]
11.

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Nodin B, Zendehrokh N, Sundström M, Jirström K.

Diagn Pathol. 2013 Jun 25;8:106. doi: 10.1186/1746-1596-8-106.

PMID:
23800114
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2485-90. doi: 10.1073/pnas.0908133107. Epub 2010 Jan 13.

PMID:
20080667
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer.

Hiroshima Y, Nakamura F, Miyamoto H, Mori R, Taniguchi K, Matsuyama R, Akiyama H, Tanaka K, Ichikawa Y, Kato S, Kobayashi N, Kubota K, Nagashima Y, Goshima Y, Endo I.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S369-78. doi: 10.1245/s10434-012-2491-3. Epub 2012 Jul 18.

PMID:
22805864
[PubMed - indexed for MEDLINE]
14.

Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.

PMID:
21837532
[PubMed - indexed for MEDLINE]
15.

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, Isayama H, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K.

J Gastroenterol. 2012 Feb;47(2):203-13. doi: 10.1007/s00535-011-0482-y. Epub 2011 Nov 1.

PMID:
22041919
[PubMed - indexed for MEDLINE]
16.

Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.

Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Yoshida K, Yagi T, Fujiwara T.

J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):223-33. doi: 10.1007/s00534-012-0531-9.

PMID:
23010994
[PubMed - indexed for MEDLINE]
17.

Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.

Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M.

Gastroenterology. 2009 Jan;136(1):206-16. doi: 10.1053/j.gastro.2008.09.063. Epub 2008 Oct 2.

PMID:
18992247
[PubMed - indexed for MEDLINE]
18.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
[PubMed - indexed for MEDLINE]
19.

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Kim ST, Sung JS, Jo UH, Park KH, Shin SW, Kim YH.

Med Oncol. 2013 Mar;30(1):328. doi: 10.1007/s12032-012-0328-3. Epub 2013 Jan 10.

PMID:
23307237
[PubMed - indexed for MEDLINE]
20.

Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.

Ren HZ, Pan GQ, Wang JS, Wen JF, Wang KS, Luo GQ, Shan XZ.

Dig Dis Sci. 2010 Sep;55(9):2552-60. doi: 10.1007/s10620-009-1065-0. Epub 2010 Jan 27.

PMID:
20108042
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk